VIVA Biotech Holdings
HKEX:1873
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
VIVA Biotech Holdings
Capital Expenditures
VIVA Biotech Holdings
Capital Expenditures Peer Comparison
Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors
Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
V
|
VIVA Biotech Holdings
HKEX:1873
|
Capital Expenditures
-ÂĄ187.8m
|
CAGR 3-Years
32%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
WuXi AppTec Co Ltd
SSE:603259
|
Capital Expenditures
-ÂĄ5.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Capital Expenditures
-ÂĄ2.6B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
N/A
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Capital Expenditures
-ÂĄ4.2B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Capital Expenditures
-ÂĄ341.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-30%
|
|
M
|
MGI Tech Co Ltd
SSE:688114
|
Capital Expenditures
-ÂĄ938.4m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is VIVA Biotech Holdings's Capital Expenditures?
Capital Expenditures
-187.8m
CNY
Based on the financial report for Dec 31, 2023, VIVA Biotech Holdings's Capital Expenditures amounts to -187.8m CNY.
What is VIVA Biotech Holdings's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-32%
Over the last year, the Capital Expenditures growth was 25%. The average annual Capital Expenditures growth rates for VIVA Biotech Holdings have been 32% over the past three years , -32% over the past five years .